EUVIMEDEUVIMED entdecken
Open Access

Tumor Volume Doubling Time of Less Than 1 Year Is Associated With a Higher Risk of Death From Medullary Thyroid Cancer

Noha Behairy iD, Anthony J Leonardi, Sriram Gubbi iD, Sonam Kumari, Mateus Pascoal, Ashwin Bharadwaj, Amr Dorgham, Elizabeth C Wright, Tomilowo Abijo, Chandra Nayan Uttarkar Vikram, Padmasree Veeraraghavan, Craig Cochran und 3 weitere

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae733 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Noha Behairy und 14 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Tumor Burden, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, NIDDK Intramural Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Tumor volume doubling time (TVDT) is emerging as a useful tool in predicting oncologic outcomes. There are limited data on the prognostic role of TVDT in metastatic medullary thyroid cancer (MTC).

Objective

The goal of this study was to assess the value of TVDT in predicting disease-specific survival (DSS) in patients with hereditary and sporadic MTC.

Methods

This was an Institutional Review Board–approved cohort study including patients with metastatic MTC having at least 3 consecutive imaging studies. TVDT of up to the 5 largest lesions per organ was calculated using a standardized formula. The association between TVDT and DSS was analyzed using Kaplan-Meier survival curves. Cox proportional regression model was used to account for confounding factors.

Results

The study sample consisted of 51 patients presenting with 286 metastatic lesions measured with 457 scans during the follow-up of 51 (IQR, 25-102) months. Median age was 19 years (IQR, 15-41), 53% female patients. Cumulative volumes of all metastatic lesions and proportion of patients with TVDT of < 1 year were higher in patients with sporadic as compared with hereditary MTC (P < .01). Factors independently associated with shorter DSS were TVDT of < 1 year based on 3 initial and 3 last scans as well as lung, brain, and prostate as the organs with the fastest growing tumor. TVDT based on 2-dimensional and 3-dimensional measurements showed strong correlation (r = 0.94, P < .05).

Conclusion

Measurements from 3 baseline and 3 most recent scans preceding follow-up visit enable calculation of TVDT and can be used as predictors of mortality from MTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsTumor BurdenCarcinoma, NeuroendocrineHumansFemaleMaleAdultYoung AdultAdolescentPrognosisCohort StudiesMiddle AgedFollow-Up StudiesTime FactorsRetrospective StudiesRisk Factors

Stichwörter der Autor:innen

CEAMEN2calcitoninmedullary thyroid carcinomatumor volume doubling time

Autor:innen und Institutionen

  • Metabolic Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Office of the Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA.

ORCID-Profile: Noha Behairy, Sriram Gubbi, Srivandana Akshintala, John Glod, Joanna Klubo-Gwiezdzinska

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • NIDDK Intramural Program
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health

Zitieren

APA

Behairy, N., Leonardi, A. J., Gubbi, S., Kumari, S., Pascoal, M., Bharadwaj, A., Dorgham, A., Wright, E. C., Abijo, T., Uttarkar Vikram, C. N., Veeraraghavan, P., Cochran, C., Akshintala, S., Glod, J., & Klubo-Gwiezdzinska, J. (2025). Tumor Volume Doubling Time of Less Than 1 Year Is Associated With a Higher Risk of Death From Medullary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae733

Vancouver

Behairy N, Leonardi AJ, Gubbi S, Kumari S, Pascoal M, Bharadwaj A, et al. Tumor Volume Doubling Time of Less Than 1 Year Is Associated With a Higher Risk of Death From Medullary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae733

BibTeX
@article{Behairy2025,
  author = {Behairy, Noha and Leonardi, Anthony J and Gubbi, Sriram and Kumari, Sonam and Pascoal, Mateus and Bharadwaj, Ashwin and Dorgham, Amr and Wright, Elizabeth C and Abijo, Tomilowo and Uttarkar Vikram, Chandra Nayan and Veeraraghavan, Padmasree and Cochran, Craig and Akshintala, Srivandana and Glod, John and Klubo-Gwiezdzinska, Joanna},
  title = {Tumor Volume Doubling Time of Less Than 1 Year Is Associated With a Higher Risk of Death From Medullary Thyroid Cancer},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae733}
}
Kostenlos starten →